CLN-619 is under clinical development by Cullinan Therapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CLN-619’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CLN-619 overview
CLN-619 is under development for the treatment of solid tumors such as Non-small cell lung cancer, cervical cancer, ovarian cancer, head and neck cancer squamous cell carcinoma, colon cancer, prostate cancer and metastatic urothelial carcinoma. The therapeutic candidate is a anti-MICA humanized IgG1 monoclonal antibody and acts by targeting MHC class I polypeptide related sequence A (MICA) and MHC class I polypeptide related sequence B (MICB). It is administered by intravenous route.
It was also under development for liver cancer.
Cullinan Therapeutics overview
Cullinan Therapeutics, formerly Cullinan Oncology Inc, is a clinical-stage biotechnology company that focuses on developing oncology therapies for cancer patients. Its CLN-619, is a monoclonal antibody, which treats solid tumors; CLN-049, is a humanized bispecific antibody for acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator, which targets multiple solid tumors; Zipalertinib, a bioavailable small-molecule, which treats patients with non-small cell lung cancer; CLN-617, a fusion protein for solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed or refractory B-cell non-Hodgkin lymphoma. Cullinan Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of CLN-619’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
